- Details
- Benjamin Lowentritt and Alicia Morgans discuss the ProVent trial, the use of sipuleucel-T in newly diagnosed prostate cancer patients on active surveillance. They discuss inclusion criteria, trial design and primary outcome measures which include assessing the efficacy of sipuleucel-T in reducing reclassification to a higher Gleason grade in patients on active surveillance. Biographies: Alicia Mor...
|
- Details
- Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...
|
- Details
- Martin Felices discusses a unique approach to using natural killer (NK) cells to target a variety of cancers. NK cells seek out abnormal cells while also producing inflammatory cytokines that induce the adaptive immune response. There is a known role of NK cells in hematologic malignancies whereas in tumor micro environments the NK cells display characteristics of exhaustion and lack of maturation...
|
- Details
- Emmanuel Antonarakis introduces the Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH). The aim of this Phase II clinical trial is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also ref...
|
- Details
- Neal Shore and Oliver Sartor cover the topic of racial disparities in prostate cancer and the use of immunotherapy particularly sipuleucel-T in the African American community. Oliver does a deep dive into the double-blind, placebo-controlled, multicenter trial, Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, involving 512 men with metastatic castration-resistant prostate cancer...
|
- Details
- Neal Shore and Evan Yu share in a discussion on the evolving role of PARP inhibitors in the treatment of mCRPC. Dr. Yu reviews the early interim results of rucaparib in the TRITON-2 study and points out the intricacies that must be considered when evaluating all the recent data involving DNA mutations. Drs. Shore and Yu discuss the class of PARP inhibitors in clinical development and what makes ea...
|
- Details
- Dr. May Sadik presents data from the SNMMI meeting highlighting a retrospective study in 45 patients with hormone naïve prostate cancer. The objective was to develop a completely automated method to quantify prostate gland update of 18F-choline in PET/CT images. The hope is that these preliminary data will lead to a better understanding of the relationship between this measure, the clinical data a...
|
- Details
- Jeremie Calais discusses his PCF funded research on 177 Lu-PSMA-617 with respect to resistance patterns that develop to treatment along with primary resistance. Drs. Calais and Ryan discuss patient and tumor characteristics for both those demonstrating effectiveness to therapy and those that develop resistance or have primary resistance. Biographies: Jeremie Calais, MD, MSc Assistant Professor at...
|
- Details
- Sima Porten speaks about the importance of TURBT and the benefits of enhanced cystoscopy to the patient. She references the new AUA/SUO guidelines recommendation for enhanced cystoscopy and the benefit of Blue Light with Cysview®. Biography: Sima P. Porten, MD, MPH, Assistant Professor, Department of Urology, UCSF Medical Center Related Content: Efficacy and Safety of Blue Light Flexible Cystoscop...
|
- Details
- Siamak Daneshmand reviews the objectives of the Blue Light Cystoscopy with Cysview® flexible study, "Efficacy and Safety of Flexible BLC with Cysview in the Surveillance of Bladder Cancer". The main objective points discussed are whether or not flexible BLC cystoscopy resulted in increase detection of non-muscle invasive bladder cancer, particularly CIS and to see if repeat use of Cysview was safe...
|
